Verastem reports 83% ORR for avutometinib+defactinib in front-line metastatic PDAC

Verastem, Inc.

Dose level 1 (RP2D) achieved 83% ORR (10/12 partial responses) in RAMP 205 trial of frontline metastatic pancreatic cancer.
Across all 5 dose cohorts, 92% (48/52) of evaluable patients showed tumor reduction.
Company plans to start registrational Phase 3 trial in front-line metastatic PDAC in 2026.
No new safety signals; adverse events consistent with previously reported profile.
R&D webcast on June 2, 2025 to discuss RAMP 205 data and VS-7375 KRAS G12D inhibitor data.

item 5.07item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.